PO.PS01.07 · 人群科学

血统驱动的乳腺癌基因转录调控:哥伦比亚人群中通过顺式和反式eQTL的调控

Ancestry-driven transcriptional regulation of breast cancer genes through cis- and trans-eQTLs in colombian populations

编号 3589 展板 7 时间 4/20 02:00–05:00 区域 Section 35 主讲 Laura Rey Vargas, BS;MS
分会场 Genetic Epidemiology 1: GxE, GWAS, Polygenic Risk Scores, and Post-GWAS
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Laura Rey-Vargas, Lina María Bejarano, Patricia López, Diego Felipe Ballen-Lozano, Silvia Juliana Serrano-Gomez

Instituto Nacional de Cancerología, Bogotá, D.C, Colombia

摘要 Abstract

中文摘要
引言:在不同人群群体中已观察到乳腺癌表型的显著差异。与非西班牙裔白人女性相比,拉丁裔女性表现出更高的侵袭性肿瘤亚型患病率和更高的死亡率。遗传血统差异被认为是影响基线组织生物学和肿瘤行为的潜在机制。具体而言,血统特异性表达数量性状位点(eQTL)可能介导这些效应。本研究旨在识别与临床相关乳腺癌基因相关的血统特异性eQTL。 方法:分析了来自哥伦比亚NCI的183名患者的肿瘤及邻近非肿瘤乳腺组织的RNA-seq数据,使用GATK4变异检出流程和TOPMed填补服务器获取基因型。使用STAR和DESeq2生成标准化基因表达矩阵,并在R中使用MatrixEQTL识别eQTL。使用RFMix推断局部血统,以筛选特定血统富集区域内的eQTL。 结果:在非肿瘤乳腺组织中,识别出234个与18个eGene相关的原住民血统特异性顺式eQTL,其中MACC1是唯一列入COSMIC的基因。此外,1,371个原住民血统特异性反式eQTL与1,001个eGene相关联。优先排序后,识别出164个显著关联,涉及由76个反式eQTL调控的31个COSMIC eGene。这些包括ERBB2、CDK6、FGFR4、LASP1和MDM2等癌基因,以及BRCA2、RB1、CDH1和ATM等抑癌基因。相反,识别出26个与四个近端eGene(ST7L、SLC35E2A、PRPF38A和ODR4)相关的欧洲血统特异性顺式eQTL。此外,160个欧洲血统特异性反式eQTL与194个eGene相关联,这些eGene显示出膜相关过程的富集,包括PRKCB和JAK3等癌基因,以及ATM和RB1等抑癌基因。由于哥伦比亚患者中非洲血统代表性较低,未对该成分进行分析。对于原住民血统特异性eQTL,位于5q13.3的12个变异与19q13.1、11p15.5和1p34.2中肿瘤相关基因之间的反式关联在癌组织中得到验证,包括MUC6、MED29和PDCD5。 结论:这些发现表明,在非肿瘤乳腺组织中,转录调控可能由原住民和欧洲血统特异性变异介导,这些变异影响在肿瘤相关通路中起关键作用的基因的表达。肿瘤组织中的验证分析表明,只有一部分原住民血统特异性eQTL可能保留反式调控效应并对乳腺癌生物学产生贡献。
查看英文原文 English abstract
Introduction: Significant disparities in breast cancer phenotypes have been observed across population groups. Latina women show a higher prevalence of aggressive tumor subtypes and increased mortality compared to non-Hispanic White women. Genetic ancestry differences have been proposed as a potential mechanism influencing baseline tissue biology and tumor behavior. Specifically, ancestry-specific expression quantitative trait loci (eQTLs) may mediate these effects. This study aimed to identify ancestry-specific eQTLs associated with clinically relevant breast cancer genes. Methods: RNA-seq data from tumor and adjacent non-tumoral breast tissue of 183 patients from the NCI of Colombia were analyzed to obtain genotypes using a GATK4 variant-calling pipeline and the TOPMed imputation server. Normalized gene expression matrices were generated with STAR and DESeq2, and eQTLs were identified using MatrixEQTL in R. Local ancestry was inferred with RFMix to filter eQTLs within regions enriched for specific ancestries. Results: In non-tumor breast tissue, 234 Indigenous ancestry-specific cis-eQTLs associated with 18 eGenes were identified, with MACC1 being the only COSMIC-listed gene. Additionally, 1,371 Indigenous ancestry-specific trans-eQTLs were linked to 1,001 eGenes. After prioritization, 164 significant associations were identified, involving 31 COSMIC eGenes regulated by 76 trans-eQTLs. These included oncogenes such as ERBB2, CDK6, FGFR4, LASP1, and MDM2, and tumor suppressor genes like BRCA2, RB1, CDH1, and ATM. Conversely, 26 European ancestry-specific cis-eQTLs associated with four proximal eGenes (ST7L, SLC35E2A, PRPF38A, and ODR4) were identified. Moreover, 160 European ancestry-specific trans-eQTLs were linked to 194 eGenes showing enrichment in membrane-related processes, including oncogenes such as PRKCB and JAK3, and tumor suppressors like ATM and RB1. Due to low African ancestry representation among Colombian patients, this component was not analyzed. For Indigenous ancestry-specific eQTLs, trans associations between 12 variants located in 5q13.3 and tumor-relevant genes in 19q13.1, 11p15.5, and 1p34.2 were validated in cancer tissue, including MUC6, MED29, and PDCD5. Conclusion: These findings suggest that in non-tumoral breast tissue, transcriptional regulation can be mediated by Indigenous and European ancestry-specific variants influencing the expression of genes with key roles in tumor-related pathways. Validation analyses in tumor tissue indicated that only a subset of Indigenous ancestry-specific eQTLs may retain trans-regulatory effects and contribute to breast cancer biology.
利益披露 Disclosure
L. Rey-Vargas, None.. L. M. Bejarano, None.. P. López, None.. D. F. Ballen-Lozano, None.. S. J. Serrano-Gomez, None.

← 返回 AACR 2026 检索